Development of selective inhibitors and substrate of matrix metalloproteinase-12. (Q33234060)

24 July 2017

Development of selective inhibitors and substrate of matrix metalloproteinase-12. (English)

1 reference

24 July 2017

Laurent Devel

1

1 reference

24 July 2017

Vassilis Rogakos

2

1 reference

24 July 2017

Arnaud David

3

1 reference

24 July 2017

Anastasios Makaritis

4

1 reference

24 July 2017

Fabrice Beau

5

1 reference

24 July 2017

Philippe Cuniasse

6

1 reference

24 July 2017

Athanasios Yiotakis

7

1 reference

24 July 2017

Vincent Dive

8

1 reference

24 July 2017

language of work or name

English

0 references

publication date

15 February 2006

1 reference

Journal of Biological Chemistry

24 July 2017

1 reference

24 July 2017

281

1 reference

24 July 2017

16

1 reference

24 July 2017

11152-11160

1 reference

Matrix metalloproteinases: a tail of a frog that became a prince

24 July 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Regulation of matrix biology by matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Matrix metalloproteinases: role in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Metalloproteinases in biology and pathology of the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Atherosclerosis and proteinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Matrix metalloproteinase inhibitors as anticancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Matrix metalloproteinases as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and pathological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Quest for selectivity in inhibition of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Impact of mobility on structure-based drug design for the MMPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Conformational variability of matrix metalloproteinases: beyond a single 3D structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Structural basis for the highly selective inhibition of MMP-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

An accurate method for determination of receptor-ligand and enzyme-inhibitor dissociation constants from displacement curves

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

All-atom empirical potential for molecular modeling and dynamics studies of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Activity-based probes for the proteomic profiling of metalloproteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Synthesis and evaluation of novel oxazoline MMP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

MMP-12 has a role in abdominal aortic aneurysms in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M600222200

21 January 2018

Identifiers

DOI

10.1074/JBC.M600222200

1 reference

24 July 2017

1 reference